52
Participants
Start Date
July 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
June 30, 2015
Baminercept
Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
Placebo
Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
University of Rochester Medical Center, Rochester
University of Pittsburgh, Pittsburgh
Johns Hopkins Medical Institute, Baltimore
Duke University Medical Center, Durham
University of Chicago, Chicago
Oklahoma Medical Research Foundation, Oklahoma City
Cedars-Sinai Medical Center, Los Angeles
Stanford University, Palo Alto
St. Francis Hospital and Medical Center, Hartford
Collaborators (1)
Autoimmunity Centers of Excellence
OTHER
Biogen
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH